2013 Fiscal Year Final Research Report
A New Perspective Of Therapies For Keloids: Application Of An Antifibrotic Medicine
| Project/Area Number |
23592637
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Plastic surgery
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMAMOTO Yuhei 北海道大学, 大学院医学研究科, 教授 (70271674)
FURUKAWA Hiroshi 北海道大学, 大学院医学研究科, 講師 (00399924)
OYAMA Akihiko 北海道大学, 北海道大学病院, 講師 (70374486)
FUNAYAMA Emi 北海道大学, 大学院医学研究科, 助教 (10533630)
SAITO Akira 北海道大学, 大学院医学研究科, 客員研究 (70507574)
MURAO Naoki 北海道大学, 北海道大学病院, 助教 (90706558)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | ケロイド / 創傷治癒学 / 抗線維化薬 / ピルフェニドン |
|---|
| Research Abstract |
Pirfenidone is a novel anti-fibrotic agent used in the treatment of idiopathic pulmonary fibrosis. Keloid is a cutaneous fibrotic disease characterized by fibroblast overproliferation and fibrogenesis such as the abnormally high production of alpha smooth muscle actin and collagen in keloid-derived fibroblasts. The effects of pirfenidone on cell proliferation, type I collagen production, and alpha-smooth muscle actin expression in keloid-derived fibroblasts were investigated in this study.
Results showed that pirfenidone significantly inhibited cell proliferation, type I collagen production, and alpha-smooth muscle actin expression in keloid-derived fibroblasts. Our study highlights the potential use of pirfenidone in the treatment of keloids.
|
